These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 19218475)

  • 21. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts.
    Liptak P; Ivanyi B
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):398-404; quiz following 404. PubMed ID: 16932468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine in Pediatric Nephrology.
    Arslansoyu Camlar S; Soylu A; Kavukçu S
    Iran J Kidney Dis; 2018 Nov; 12(6):319-330. PubMed ID: 30595561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
    Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A
    Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct effects of calcineurin dependent and independent immunosuppressants on endotoxaemia-induced nephrotoxicity in rats: Role of androgens.
    Elzokm SS; Fouda MA; Abdel Moneim RA; El-Mas MM
    Clin Exp Pharmacol Physiol; 2021 Sep; 48(9):1261-1270. PubMed ID: 34042216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus-induced nephrotoxicity and genetic variability: a review.
    Gijsen VM; Madadi P; Dube MP; Hesselink DA; Koren G; de Wildt SN
    Ann Transplant; 2012; 17(2):111-21. PubMed ID: 22743729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.
    Ziolkowski J; Paczek L; Senatorski G; Niewczas M; Oldakowska-Jedynak U; Wyzgal J; Sanko-Resmer J; Pilecki T; Zieniewicz K; Nyckowski P; Patkowski W; Krawczyk M
    Transplant Proc; 2003 Sep; 35(6):2307-9. PubMed ID: 14529923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
    Nankivell BJ; Borrows RJ; Fung CL; O'Connell PJ; Chapman JR; Allen RD
    Transplantation; 2004 Aug; 78(4):557-65. PubMed ID: 15446315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
    Bai JP; Lesko LJ; Burckart GJ
    Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
    Issa N; Kukla A; Ibrahim HN
    Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
    Olyaei AJ; de Mattos AM; Bennett WM
    Drug Saf; 1999 Dec; 21(6):471-88. PubMed ID: 10612271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
    Pallet N; Legendre C
    Pharmacogenomics; 2010 Oct; 11(10):1491-501. PubMed ID: 21047207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nephrotoxicity of new and old immunosuppressive drugs.
    Bennett WM
    Ren Fail; 1998 Sep; 20(5):687-90. PubMed ID: 9768435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.